- Clinical Trials
Genprex Inc (NASDAQ:GNPX) Chairman and CEO Rodney Varner tells Proactive Investors the biotech has initiated the first phase of branding for its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the USAN Council.
Genprex, Inc. (NASDAQ:GNPX) Chairman and Chief Executive Officer, Rodney Varner, updates Proactive Investors on the latest developments with the Texas-based company’s non-small cell lung cancer drug, including positive study results done in humanized mice.
Genprex, Inc. (NASDAQ:GNPX) Chairman and CEO, Rodney Varner, tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate by retaining pharmaceutical branding agency, Addison Whitney, for the development of its non-proprietary and brand drug name.
Genprex Inc (NASDAQ: GNPX) CEO Rodney Varner tells Proactive Investors that its collaborators from the University of Texas MD Anderson Cancer Center presented positive preclinical data linked to the company’s Oncoprex immunogene therapy for the treatment of lung cancer at the American Association of Cancer Research meeting.
President and Chief Operating Officer, Julien Pham, MD, MPH, delivers a presentation about the company’s unique, leading-edge gene therapies and participated in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV.
Speaking on the sidelines of Biotech Showcase 2019, Julien Pham, President and COO of Genprex, describes how the company is using a technology platform which wraps the TUSC2 gene in a cholesterol nanoparticle to create Oncoprex™ which, in combination with erlotinib, is in Phase II testing against NSCLC.
Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations. According to Pham, Stevens will support clinical development programs for the company’s immunogene therapy Oncoprex, which is being evaluated in…
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado at the MicroCap Conference in New York. The clinical-stage gene therapy company has reached a deal with Aldevron, a contract manufacturer, to receive a supply of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in its clinical…
Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado on the Austin, Texas-based biopharma’s operations in the last few months, notably raising $10mln to be used toward continuing the company’s clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed…
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company’s non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about…